1,720,987 research outputs found
Quality of Evidence submitted to NICE Technology Appraisals (2000-2020)
No full textThis file provides a data set on 409 Technology Appraisals (TAs) issued by NICE between March 2000 when TA1 was published and September 11, 2019 when TA 600 was published. For each of these TAs, there are analyses including a score for their Data Quality, QoL Data Quality, Quality of Submitted Evidence, Overall Quality of Evidence for decision, and Quality of Submitted RCTs. A legend is in the file's second tab
Blockchain's potential to improve clinical trials-an essay by Leeza Osipenko
Get PDFThere’s more to this tamperproof technology than bitcoin. It could be used to improve the administration of clinical trials, ensuring transparency and yielding better quality data, writes Leeza Osipenk
The Origin and Clinical Benefit of First-in-Class Drugs that entered the French market between 2008 and 2018
No full textThis file contains a data set of 135 First-in-class medicines that entered the French market between 2008 to 2018. For each drug we present data on provenance (inventor of the drug) and clinical benefit grading by Haute Autorité de Santé (HAS) and Prescrire. A legend on matching clinical grading scale can be found on tab 3 of the document
Provenance, Added Clinical Benefit and Therapeutic Area of 632 medicines that entered the French market between 2008 and 2018
No full textThis file contains a data set of 632 medicines that entered the French market between 2008 to 2018. 529 medicines are single drugs and 103 are combination medicines. For each drug we present data on provenance (inventor of the drug) and sources referencing our searches for origins of each medicine. We also present added clinical benefit data for all 632 medicines based on HAS and Prescrire matched grading scale as well as therapeutic area of each medicinal product in which the clinical benefit grading was sourced (highest clinical benefit grading attained by the product in the indication based on Prescrire grading). The file also contains data on the medicines approved by the FDA in the United State
Quality of Evidence submitted to NICE Technology Appraisals (2000-2020)
No full textThis file provides a data set on 409 Technology Appraisals (TAs) issued by NICE between March 2000 when TA1 was published and September 11, 2019 when TA 600 was published. For each of these TAs, there are analyses including a score for their Data Quality, QoL Data Quality, Quality of Submitted Evidence, Overall Quality of Evidence for decision, and Quality of Submitted RCTs. A legend is in the file's second tab
Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
No full textOBJECTIVES: To assess the extent and type of data redaction in all active technology appraisals (TA) and highly specialised technology (HST) evaluations issued by the National Institute for Health and Care Excellence (NICE) from its conception of the institute to September 2019. To propose policy recommendations for transparency. METHODS: Structured audit to establish extent of data redaction-proportion of appraisals and specific data categories and assess redaction by: indication, appraisal process, manufacturer, type of data-price, adverse events (AEs), clinical (excluding AEs), incremental quality-adjusted life-years. Longitudinal analysis over 20 years. RESULTS: All TAs with available documentation and active recommendations (n=408) and HSTs (n=10) published from March 2000 to 11 September 2019 have been assessed for data redaction. Overall, 333 TAs (81.6%) have data redaction, 86 (25.8%) of them are heavily redacted. Clinical data (excluding AEs) are redacted in 268 (65.7%) appraisals, AE data in 128 (31.4%), price in 238 (58.3%). In total, 87% of oncology appraisals have redacted data vs 78% of non-oncology appraisals. 91% of single TAs have redacted data vs 59% of multiple TAs. 25% of final guidance documents (e.g. Final Appraisal Determination - FAD) do not report one or more instance of clinical data. Data redaction increased substantially over time, and is currently at its highest level with 100% of TAs having at least some data redaction in 2019/2020, 96% of appraisals in 2018/2019% and 94% of appraisals in 2017/2018. All 10 HST evaluations have redacted data, with 4 of them being heavily redacted. CONCLUSIONS: Documents supporting NICE TA and HST recommendations are significantly redacted, thereby concealing clinical and economic data of importance to patients, clinicians and researchers. Documents remain redacted on the NICE website for years. Policy change is required to ensure transparency of data underpinning NICE's decisions
The Locked-down: we need more than headline statistics to understand the impact of Covid-19
Get PDFFor governments and individuals much of our understanding of the Covid-19 pandemic has been mediated through metrics of cases and deaths and shaped by heartbreaking personal stories. In this post, Leeza Osipenko argues that such metrics only scratch the surface of the impact of the Covid-19 pandemic and makes the case for more expansive data collection to understand how Covid-19 is reshaping society
Ledger of data redactions in NICE Technology Appraisals
No full textThe file, 'data_redactions_ledger_NICE', provides a complete data set on 600 Technology Appraisals (TAs) and 10 Highly Specialised Technologies (HSTs) issued by NICE between March 2000 when TA1 was published and September 11, 2019 when TA 600 was published. Data are extracted for 408 active TAs and 10 HST. Remaining appraisals are recorded in the replaced/terminated tabs. The document is organised in 13 different tabs. A comprehensive description of the file's structure is in the first tab
Point of care tests for tuberculosis (TB) : economic analysis report
Get PDFA number of clinical/disease areas have been prioritised by the TSB and DH for the DIIA Innovation Platform. To support commissioning of technology developments in the area of tuberculosis detection in humans, a scoping review has been undertaken to help identify the specific requirements for new diagnostic test development and likely payback in the area of point of care (POC) tuberculosis tests in the UK.
There has been a gradual rise in the number of tuberculosis (TB) cases observed in the UK over the last 20 years, with a 4.2% rise in 2009 giving an overall 9,040 TB cases diagnosed or 15 cases per 100,000 population [1].
The aims of this economic review are to identify available information on the following for tuberculosis (TB):
- economic burden of disease in the UK;
- current NHS cost of TB detection and cost of treating identified TB cases;
- evidence on cost-effectiveness of current tests for detection of active and latent TB infection; and
- estimates of the economic benefits which new POC tests might provide in the UK
- …
